Neuroinflammatory processes play a significant role in the pathogenesis of Parkinson's disease (PD). Epidemiologic, animal, human, and therapeutic studies all support the presence of a neuroinflammatory cascade in disease. This is highlighted by the neurotoxic potential of microglia. In steady-state, microglia serve to protect the nervous system by acting as debris scavengers, killers of microbial pathogens, and regulators of innate and adaptive immune responses. In neurodegenerative diseases, activated microglia affect neuronal injury and death through production of glutamate, pro-inflammatory factors, reactive oxygen species, quinolinic acid among others and by mobilization of adaptive immune responses and cell chemotaxis leading to transendothelial migration of immunocytes across the blood-brain barrier and perpetuation of neural damage. As disease progresses, inflammatory secretions engage neighboring glial cells, including astrocytes and endothelial cells, resulting in a vicious cycle of autocrine and paracrine amplification of inflammation perpetuating tissue injury. Such pathogenic processes contribute to neurodegeneration in PD. Research from others and our own laboratories seek to harness such inflammatory processes with the singular goal of developing therapeutic interventions that positively affect the tempo and progression of human disease.
Introduction
Parkinson's disease (PD) is the most common movement disorder and second, only to Alzheimer's disease, as a cause of age-linked neurodegeneration [1] [2] [3] . The primary pathological characteristics of PD are the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and reductions in their termini within the dorsal striatum [4] . These lead to profound and irreversible striatal dopamine loss. Indeed, extrapolated cell modeling data [5] demonstrate that 100-200 SNpc neurons degenerate per day during PD [6] . However, the SNpc is not the sole site for neuronal damage involving, in measure, the locus coeruleus, raphe nuclei, and the nucleus basalis of Meynert. Nonetheless, progressive degeneration of the nigrostriatal pathway is the predominant mediator for clinical manifestations of PD including rigidity, resting tremor, slowness of voluntary movement, postural instability, and in some cases, dementia [2] .
In regards to disease epidemiology, the mean age of PD onset is 55. This increases dramatically with time [7] . While the cause of PD is not known, data obtained from familial disease and from animal models of PD support a pathogenic process that is closely linked to mitochondrial
